menu
    • menu

    Company profile for Silexion Therapeutics

    NEW Drugs in Dev: 2
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Silexion is a biotechnology company specializing in the development of innovative solutions for targeted drug delivery and personalized medicine. Our mission is to harness advanced technologies to create therapies that improve patient outcomes and enhance the effectiveness of treatments. With a strong focus on research and development, we aim to address unmet medical needs in various therapeutic areas, ensuring that our soluti...
    Silexion is a biotechnology company specializing in the development of innovative solutions for targeted drug delivery and personalized medicine. Our mission is to harness advanced technologies to create therapies that improve patient outcomes and enhance the effectiveness of treatments. With a strong focus on research and development, we aim to address unmet medical needs in various therapeutic areas, ensuring that our solutions are both safe and effective. At Silexion, we are committed to transforming healthcare through innovation, collaboration, and a dedication to excellence in every aspect of our work.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Silexion TherapeuticsIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    2 Hama'ayan Street, Modi'in-Maccabim-Reut
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://silexion.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Silexion Therapeutics Reports Q1 2026 Financial Results
    Silexion Therapeutics Reports Q1 2026 Financial Results

    18 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/18/3296613/0/en/silexion-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update.html

    GLOBENEWSWIRE
    18 May 2026
    Share Share
    Silexion Therapeutics Starts GMP Manufacturing Of SIL204
    Silexion Therapeutics Starts GMP Manufacturing Of SIL204

    13 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/13/3293916/0/en/silexion-therapeutics-announces-initiation-of-gmp-clinical-supply-manufacturing-of-sil204-with-leading-global-cdmo-and-new-approval-of-phase-2-3-trial-from-tel-aviv-sourasky-medica.html

    GLOBENEWSWIRE
    13 May 2026
    Share Share
    Silexion Therapeutics Submits SIL204 Phase 2/3 Trial Application
    Silexion Therapeutics Submits SIL204 Phase 2/3 Trial Application

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282684/0/en/silexion-therapeutics-announces-successful-submission-of-phase-2-3-clinical-trial-application-to-germany-s-bfarm-for-sil204-in-kras-driven-locally-advanced-pancreatic-cancer.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Silexion Therapeutics Approved For Phase 2/3 Trial Of SIL204
    Silexion Therapeutics Approved For Phase 2/3 Trial Of SIL204

    24 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/24/3261422/0/en/Silexion-Therapeutics-Receives-Approval-from-Israeli-Ministry-of-Health-to-Initiate-Phase-2-3-Clinical-Trial-of-SIL204-in-Locally-Advanced-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    24 Mar 2026
    Share Share
    Silexion Therapeutics Reports 2025 Financial Results
    Silexion Therapeutics Reports 2025 Financial Results

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257725/0/en/Silexion-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Silexion Therapeutics Urges Shareholders To Vote Before March 16
    Silexion Therapeutics Urges Shareholders To Vote Before March 16

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250105/0/en/Silexion-Therapeutics-Urges-Shareholders-to-Vote-Ahead-of-March-16-Extraordinary-General-Meeting.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search